메뉴 건너뛰기




Volumn 44, Issue 6, 2014, Pages 1548-1556

INSTEAD: A randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; INDACATEROL; SALBUTAMOL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; GLUCOCORTICOID; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

EID: 84916240063     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00126814     Document Type: Article
Times cited : (114)

References (21)
  • 1
    • 0003736032 scopus 로고    scopus 로고
    • Global Initiative for Chronic Obstructive Lung Disease, Date last updated: June 11, 2014. Date last accessed: October 14, 2014
    • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014 Available from: www.goldcopd.org/uploads/users/files/GOLD-Report-2014-Jun11.pdf Date last updated: June 11, 2014. Date last accessed: October 14, 2014.
    • (2014) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
  • 2
    • 69249124565 scopus 로고    scopus 로고
    • Inhaled corticosteroids in COPD: The case against
    • Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13-16.
    • (2009) Eur Respir J , vol.34 , pp. 13-16
    • Suissa, S.1    Barnes, P.J.2
  • 3
    • 84899491531 scopus 로고    scopus 로고
    • Understanding the GOLD 2011 Strategy as applied to a real-world COPD population
    • Vestbo J, Vogelmeier C, Small M, et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med 2014; 108: 729-736.
    • Respir Med , vol.2014 , Issue.108 , pp. 729-736
    • Vestbo, J.1    Vogelmeier, C.2    Small, M.3
  • 4
    • 78049430514 scopus 로고    scopus 로고
    • Inhaled corticosteroids and the risks of diabetes onset and progression
    • Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
    • (2010) Am J Med , vol.123 , pp. 1001-1006
    • Suissa, S.1    Kezouh, A.2    Ernst, P.3
  • 5
    • 84875990675 scopus 로고    scopus 로고
    • Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD
    • Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013; 143: 1018-1024.
    • (2013) Chest , vol.143 , pp. 1018-1024
    • Kim, J.H.1    Park, J.S.2    Kim, K.H.3
  • 6
    • 84870469745 scopus 로고    scopus 로고
    • Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
    • Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 2012; 28: 1959-1967.
    • (2012) Curr Med Res Opin , vol.28 , pp. 1959-1967
    • Thornton Snider, J.1    Luna, Y.2    Wong, K.S.3
  • 7
    • 0030859363 scopus 로고    scopus 로고
    • Use of inhaled corticosteroids and the risk of cataracts
    • Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8-14.
    • (1997) N Engl J Med , vol.337 , pp. 8-14
    • Cumming, R.G.1    Mitchell, P.2    Leeder, S.R.3
  • 8
    • 50249112115 scopus 로고    scopus 로고
    • Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids
    • Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008; 38: 1451-1458.
    • (2008) Clin Exp Allergy , vol.38 , pp. 1451-1458
    • Weatherall, M.1    James, K.2    Clay, J.3
  • 9
    • 84857283681 scopus 로고    scopus 로고
    • Indacaterol: A review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease
    • McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012; 72: 543-563.
    • (2012) Drugs , vol.72 , pp. 543-563
    • McKeage, K.1
  • 10
    • 79953024950 scopus 로고    scopus 로고
    • Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study
    • Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105: 719-726.
    • (2011) Respir Med , vol.105 , pp. 719-726
    • Korn, S.1    Kerwin, E.2    Atis, S.3
  • 11
    • 79953026850 scopus 로고    scopus 로고
    • Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebocontrolled comparison
    • Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur Respir J 2011; 37: 273-279.
    • (2011) Eur Respir J , vol.37 , pp. 273-279
    • Kornmann, O.1    Dahl, R.2    Centanni, S.3
  • 12
    • 34147214922 scopus 로고    scopus 로고
    • Global Initiative for Chronic Obstructive Lung Disease, Date last updated: April 11, 2011. Date last accessed: October 14, 2104
    • Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2010. Available from: www.goldcopd.org/uploads/users/files/GOLDReport-April112011.pdf Date last updated: April 11, 2011. Date last accessed: October 14, 2104.
    • (2010) Global Strategy for the Diagnosis, Management and Prevention of COPD
  • 13
    • 0037322464 scopus 로고    scopus 로고
    • Minimal important difference of the transition dyspnoea index in a multinational clinical trial
    • Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21: 267-272.
    • (2003) Eur Respir J , vol.21 , pp. 267-272
    • Witek, T.J.1    Mahler, D.A.2
  • 14
    • 20144362569 scopus 로고    scopus 로고
    • St. George's respiratory questionnaire: MCID
    • Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
    • (2005) COPD , vol.2 , pp. 75-79
    • Jones, P.W.1
  • 16
    • 84874694081 scopus 로고    scopus 로고
    • Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD
    • Price D, Yawn B, Brusselle G, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22: 92-100.
    • (2013) Prim Care Respir J , vol.22 , pp. 92-100
    • Price, D.1    Yawn, B.2    Brusselle, G.3
  • 17
    • 0041865230 scopus 로고    scopus 로고
    • Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies
    • Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53.
    • (2003) Am J Respir Crit Care Med , vol.168 , pp. 49-53
    • Suissa, S.1
  • 18
    • 80051593508 scopus 로고    scopus 로고
    • Withdrawal of inhaled corticosteroids in individuals with COPD - A systematic review and comment on trial methodology
    • Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res 2011; 12: 107.
    • (2011) Respir Res , vol.12 , pp. 107
    • Nadeem, N.J.1    Taylor, S.J.2    Eldridge, S.M.3
  • 19
    • 84903812277 scopus 로고    scopus 로고
    • Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: A real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)
    • Rossi A, Guerriero M, Corrado A, et al. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014; 15: 77.
    • (2014) Respir Res , vol.15 , pp. 77
    • Rossi, A.1    Guerriero, M.2    Corrado, A.3
  • 20
    • 33847172367 scopus 로고    scopus 로고
    • Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    • Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
    • (2007) N Engl J Med , vol.356 , pp. 775-789
    • Calverley, P.M.1    Anderson, J.A.2    Celli, B.3
  • 21
    • 70249107150 scopus 로고    scopus 로고
    • Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study
    • Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
    • (2009) Respir Res , vol.10 , pp. 59
    • Jenkins, C.R.1    Jones, P.W.2    Calverley, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.